Compare WFRD & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFRD | DFTX |
|---|---|---|
| Founded | 1941 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.9B |
| IPO Year | 2014 | 2020 |
| Metric | WFRD | DFTX |
|---|---|---|
| Price | $94.64 | $42.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $103.22 | $38.50 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $4,331,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $45.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.74 | $14.62 |
| 52 Week High | $113.15 | $49.70 |
| Indicator | WFRD | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.01 | 49.67 |
| Support Level | $82.64 | $40.29 |
| Resistance Level | $97.79 | $49.13 |
| Average True Range (ATR) | 3.27 | 2.71 |
| MACD | 1.11 | -0.50 |
| Stochastic Oscillator | 98.13 | 22.69 |
Weatherford provides oilfield services and equipment to national, integrated, public, and private oil and gas operators. It operates across multiple upstream markets, including offshore, the rest of the world onshore, and US onshore, where Weatherford has limited exposure. The Middle East, North Africa, and Asia account for over 25% of sales. Weatherford also offers manufacturing, research, and training services. Performance is reported through three segments: drilling and evaluation, well construction and completions, and production and intervention.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.